Prognostic factors of survival for patients with stage III and stage IV epithelial ovarian cancer

Rongyu Zang,ZhiYi Zhang,Ziting Li,Shumo Cai,Jie Chen,MeiQin Tang

2001-01-01

Abstract:Purpose: To investigate the prognostic factors of survival in patients with advanced epithelial ovarian cancer (EOC). Methods: 265 and 71 patients with stage III and stage IV EOC respectively computerized statistical analyses, using SPSS software, were performed to estimate the survival. The survival rate was calculated by life table, with survival difference tested by log-rank test. Cox stepwise regression model was used to detect prognostic factors of survival. Results: 120 (45. 28 %) stage III patients were optimally cytoreduced during primary surger, with an estimated five-year survival of 38. 56%. Residual disease was also a significant prognostic determinant of survival in patients with stage IV EOC, mainly in those with malignant pleural effusion and surpraclavicular lymphadenopathy. Cox stepwise regression analysis revealed that residual disease (P = 0. 000 0), the muscle of uteri corpus or cervix involved by the tumor (P = 0. 002 9), refractory ascites (P = 0. 000 0), adjuvant chemotherapy, and cell types (P = 0. 003 8) were identified to be independent prognostic factors of survival for stage III EOC patients. Neoadjuvant chemotherapy was associated with progression-free survival. Acites was also an independent prognostic factors of survival for stage IV disease (P = 0. 004 3). Conclusions: Residual disease, refractory ascites, types of histology, and adjuvant chemotherapy were prognostic factors of survival for patients with advanced EOC. Besides residual disease, ascites was an important prognostic factors of survival of stage IV disease.